Method, compositions and kits for increasing the oral...

Details Method, compositions and kits for increasing the oral... Method, compositions and kits for increasing the oral...

2006-05-09

2006-05-09

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S449000

Reexamination Certificate

active

07041640

ABSTRACT:
A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent. A method of treating mammalian patients suffering from diseases responsive to target agents with poor oral bioavailability, as well as oral dosage forms containing such target agents, combination oral dosage forms containing bioavailability-enhancing agents and target agents and kits containing enhancing and target agent dosage forms and dosing information for the co-administration of the same are also disclosed.

REFERENCES:
patent: 5112817 (1992-05-01), Fukazawa et al.
patent: 5114951 (1992-05-01), King
patent: 5118493 (1992-06-01), Kelley et al.
patent: 5124330 (1992-06-01), King
patent: 5124338 (1992-06-01), King
patent: 5124339 (1992-06-01), King
patent: 5166207 (1992-11-01), Smith
patent: 5208238 (1993-05-01), King
patent: 5300282 (1994-04-01), King
patent: 5346897 (1994-09-01), King
patent: 5364843 (1994-11-01), King
patent: 5387685 (1995-02-01), Powell et al.
patent: 5395610 (1995-03-01), King
patent: 5405843 (1995-04-01), Fukazawa et al.
patent: 5416091 (1995-05-01), King
patent: 5438072 (1995-08-01), Bobee et al.
patent: 5525590 (1996-06-01), Bollinger et al.
patent: 5646176 (1997-07-01), Golik et al.
patent: 5670536 (1997-09-01), Durr et al.
patent: 5750561 (1998-05-01), Bastart et al.
patent: 5968972 (1999-10-01), Broder et al.
patent: 5972992 (1999-10-01), Carver et al.
patent: 6004927 (1999-12-01), Benet et al.
patent: 6096331 (2000-08-01), Desai et al.
patent: 6245805 (2001-06-01), Broder et al.
patent: 6610735 (2003-08-01), Broder et al.
patent: 413828 (1990-11-01), None
patent: WO 92/12132 (1992-07-01), None
patent: WO 95/20980 (1995-08-01), None
patent: WO 9727855 (1997-08-01), None
Duverne, et al., Antimicrobial Agents and Chemotherapy, 36(11):2462-2467 (1992).
Vinceneux, et al., International Journal of Clinical Pharmacology, Therapy and Toxixology, 24(3):153-158 (1986).
Benet et al., J. Cont. Release, vol. 39, pp. 139-143 (1996).
Brock et al., Cancer Res., vol. 55, pp. 459-462 (1995).
Wils et al., Biochem. Pharm., vol. 48, pp. 1528-1530 (1994).
Kloke et al., Klin Wochenschr., vol. 63, pp. 1081-1082 (1985).
Chang et al., Clin. Pharm. Therap., vol. 59, pp. 297-303 (1996).
Chiu et al., Proc. Of Am. Assoc. Pharm. Sci., Abstract PDD 7428 (Nov. 1995).
Bal et al., Proc. of Am. Assoc. Pharm. Sci., Abstract PDD 7459 (Nov. 1995).
Germann et al., J. Bioenerg. Biomemb., vol. 27, pp. 53-61 (1995).
Joel et al., Cancer Chemother. Pharmac., vol. 37, pp. 125-133 (1995).
Schinkel et al., J. Clin Invest., vol. 96, pp. 1698-1705 (1995).
Scheffer et al., Nature Medicine, vol. 1, No. 6, pp. 578-582 (1995).
Lum et al., Drug Resistance in Clin. Onc. and Hematology, vol. 9, No. 2, pp. 319-336 (1995).
Fracasso et al., Proc. of ASCO, vol. 14, Abstract 1585, p. 486 (1995).
Bissey, Euro J. Cancer, vol. 31A, Sup. 4, pp. S1-S6 (1995).
Leu et al., Cancer Chem. Pharmac., vol. 35, No. 5, pp. 432-436 (1995).
Keogh et al., N.E. J. Med., vol. 333, No. 10, pp. 628-633 (1995).
Leveque et al., Anticancer Res. vol. 15, pp. 331-336 (1995).
Montaseri et al., Pharm. Res., vol. 12, No. 9, p. S-429, Abstract PPDM 8411 (1995).
Muller, Proc. Nat. Acad. Sci., vol. 91, pp. 13033-13037 (1994).
Pouvelle et al., J. Clin. Invest., vol. 94, pp. 413-417 (1994).
Schinkel et al., Cell, vol. 77, pp. 491-502 (1994).
Fisher et al., Proc. of ASCO, vol. 13, Abstract 369, p. 144 (1994).
Siegsmund et al., J. Urol., vol. 151, pp. 485-491 (1994).
Grant et al., Cancer Res., vol. 54, pp. 357-361 (1994).
Cresteil et al., Cancer Res., vol. 54, pp. 386-392 (1994).
Bartlett et al., J. Clin. Onc., vol. 12, No. 4, pp. 835-842 (1994).
Sikic et al., Anticancer Drug Resistance: Adv. Molec. Clin. Res., pp. 149-165 (1994).
Kumar et al., J. of Pharmac. and Exp. Therapeutics., vol. 268, No. 3, pp. 1160-1165 (1994).
Lepage et al., Current Op. in Neph. And Hypert., vol. 2, pp. 735-743 (1993).
Lum et al., Clin. Onc., vol. 10, No. 10, pp. 1635-1642 (1992).
Loehrer, Seminars in Onc., vol. 18, No. 6, Sup. 14, pp. 48-52 (1992).
Keller et al., Int. J. Cancer, vol. 51, pp. 433-438 (1992).
Hunter et al., Pharma. Res. 10(5):743-749 (1993).
Kobayashi, Proc. Ann. Meet. Am. Soc. Clin. Oncol. 15:A14889 (1996).
Harris et al., Cancer Research, 54:4026-35 (1994).
Tsuruo, Jpn. J. Cancer Chemotherapy, 21(7):962:67, (1994) (English abstract only).
Baba et al., Cancer Chemother. Pharmacol. 36(5):361-67 (1995).
Terao et al., J. Pharmacy & Pharmacol. 48:1083-1089(1996).
Sato, et al., Cancer Chemother. Pharmacol.; 35(4):271-277 (1995).

Affiliated with

Also associated with

Rating

Method, compositions and kits for increasing the oral... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method, compositions and kits for increasing the oral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method, compositions and kits for increasing the oral... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3599361